Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.49 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21815267 | 0.89 | DRD2 (0.50) | DRD2EPHX1KCNA3SIGMAR1TDP1 | |
| SCHEMBL6700 | 0.84 | DRD2 (0.53) | DRD2EPHX1MAOAMAOBSIGMAR1 | |
| SCHEMBL19571350 | 0.83 | DRD2 (0.47) | DRD2EPHX1MAOAMAOBSIGMAR1 | |
| SCHEMBL24619896 | 0.83 | DRD2 (0.54) | DRD2EPHX1MAOAMAOBSIGMAR1 | |
| SCHEMBL18947871 | 0.83 | DRD2 (0.54) | DRD2EPHX1SIGMAR1TDP1CACNA1H | |
| SCHEMBL22699069 | 0.83 | DRD2 (0.54) | DRD2EPHX1SIGMAR1TDP1CACNA1H | |
| SCHEMBL8254760 | 0.82 | DRD2 (0.64) | DRD2SIGMAR1TDP1CACNA1HGAA | |
| SCHEMBL5033974 | 0.81 | DRD2 (0.48) | DRD2MAOAMAOBSIGMAR1TDP1 | |
| SCHEMBL26813557 | 0.81 | KCNA3 (0.53) | DRD2EPHX1KCNA3 | |
| SCHEMBL22703621 | 0.80 | DRD2 (0.54) | DRD2EPHX1SIGMAR1TDP1CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10259825-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| US-10259825-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
| EP-3421476-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | Melinta Therapeutics, Inc. (US) | 2019-01-02 | — | — | EP | disclosed |
| EP-2488532-B1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-2488532-B1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MELINTA THERAPEUTICS INC (US) | 2018-05-09 | — | — | EP | disclosed |
| US-20170320892-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | SILICON VALLEY BANK | 2017-11-09 | — | — | US | disclosed |
| US-20170320892-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | SILICON VALLEY BANK | 2017-11-09 | — | — | US | disclosed |
| US-9573962-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-9573962-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| US-20150274752-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2015-10-01 | — | — | US | disclosed |
| US-20150274752-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2015-10-01 | — | — | US | disclosed |
| US-9023843-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-9023843-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| EP-2488532-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | Rib-X Pharmaceuticals, Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120202792-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202792-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2011047320-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011047320-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274752-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | LPO, MPO, CAT | DRD2 2557/4885EPHX1 2356/4885KCNA3 3587/4885 |
| US-10259825-B2 | Antimicrobial compounds and methods of making and using the same | LPO, MPO, CAT | DRD2 2557/4885EPHX1 2356/4885KCNA3 3587/4885 |
| US-20120202792-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | LPO, MPO, CAT | DRD2 2557/4885EPHX1 2356/4885KCNA3 3587/4885 |
| US-20170320892-A1 | Antimicrobial Compounds And Methods Of Making And Using The Same | LPO, MPO, CAT | DRD2 2557/4885EPHX1 2356/4885KCNA3 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.